Russell Frank Company’s Cytokinetics CYTK Stock Holding History

Russell Frank Company’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$2.39M	Sell	338,825 -110,173	-25%	-$805K	﹤0.01%	1765
2015 Q4	$4.72M	Buy	+448,998	New	+$4.4M	0.01%	1321
2015 Q3	–	Sell	-33,033	Closed	-$222K	–	3004
2015 Q2	$222K	Sell	33,033 -59,900	-64%	-$393K	﹤0.01%	2785
2015 Q1	$630K	Sell	92,933 -26,500	-22%	-$198K	﹤0.01%	2335
2014 Q4	$956K	Buy	119,433 +109,333	+1,083%	+$469K	﹤0.01%	2164
2014 Q3	$36K	Buy	+10,100	New	+$42.4K	﹤0.01%	2746
2014 Q2	–	Sell	-54,971	Closed	-$266K	–	2786
2014 Q1	$266K	Buy	+54,971	New	+$497K	﹤0.01%	2519
2013 Q4	–	Sell	-1,545	Closed	-$12K	–	2858
2013 Q3	$12K	Buy	+1,545	New	+$16.6K	﹤0.01%	3274

Other funds holding CYTK

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

LPU

Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Russell Frank Company's CYTK Position: Q1 2016 in Review

Russell Frank Company reduced its Cytokinetics (CYTK) stake by 25% in Q1 2016, selling an estimated $805K and leaving 338,825 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1765.

Russell Frank Company first reported a position in CYTK in Q3 2013 and has held it in 8 quarters since. The position peaked at $4.72M in Q4 2015. 109 funds tracked by Wall St. Rank hold CYTK as of Q1 2016.

Russell Frank Company held 338,825 shares of Cytokinetics worth $2.39M as of Q1 2016.
Russell Frank Company sold 110,173 Cytokinetics shares in Q1 2016, an estimated $805K.
Cytokinetics made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #1765 holding.
Russell Frank Company first reported a position in Cytokinetics in Q3 2013 and has held it in 8 quarters since.
Russell Frank Company's Cytokinetics position peaked at $4.72M in Q4 2015.
109 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.